UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) (Zip Code) |
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class |
Trading |
Name of each exchange | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 5.07 | Submission of Matters to a Vote of Security Holders. |
On September 27, 2024, Molecular Templates, Inc. (the “Company”) held its 2024 annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, a quorum of 4,676,739 shares of the Company’s common stock, or 71.03% of the outstanding shares of common stock entitled to vote as of the record date of August 1, 2024, were present in person or represented by proxy. At the Annual Meeting, the stockholders: (1) elected Corsee Sanders, Ph.D. to the Company’s Board of Directors as a Class II director for a term of three years to serve until the 2027 annual meeting of stockholders and until her successor is elected and qualified or until her earlier death, resignation or removal (“Election of Director”); (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Auditor Ratification”); and (3) approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the proxy statement for the meeting (“Advisory Vote on Executive Compensation”). A more complete description of each of these matters is set forth in the Company’s proxy statement.
The number of votes cast in favor or against by the stockholders and the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.
| 1. | Election of Director |
| Nominee | Shares Voted For |
Shares Voted Against |
Shares Abstaining |
Broker Non-votes | ||||
| Corsee Sanders, Ph.D. |
3,031,323 | 553,546 | 139 | 1,091,731 |
| 2. | Auditor Ratification |
| Shares Voted For |
Shares Voted Against |
Shares Abstaining | ||
| 4,639,921 |
28,744 |
8,074 |
| 3. | Advisory Vote on Executive Compensation |
| Shares Voted For |
Shares Voted Against |
Shares Abstaining |
Broker Non-votes | |||
| 3,561,675 |
22,865 | 468 | 1,091,731 |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Molecular Templates, Inc. | ||||||
| Dated: September 27, 2024 | ||||||
| By: | /s/ Eric E. Poma, Ph.D. | |||||
| Name: Eric E. Poma, Ph.D. | ||||||
| Title: Chief Executive Officer | ||||||
3
Document and Entity Information |
Sep. 27, 2024 |
|---|---|
| Cover [Abstract] | |
| Security Exchange Name | NASDAQ |
| Amendment Flag | false |
| Entity Central Index Key | 0001183765 |
| Document Type | 8-K |
| Document Period End Date | Sep. 27, 2024 |
| Entity Registrant Name | Molecular Templates, Inc. |
| Entity Incorporation State Country Code | DE |
| Entity File Number | 001-32979 |
| Entity Tax Identification Number | 94-3409596 |
| Entity Address, Address Line One | 9301 Amberglen Blvd |
| Entity Address, Address Line Two | Suite 100 |
| Entity Address, City or Town | Austin |
| Entity Address, State or Province | TX |
| Entity Address, Postal Zip Code | 78729 |
| City Area Code | (512) |
| Local Phone Number | 869-1555 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, $0.001 par value per share |
| Trading Symbol | MTEM |
| Entity Emerging Growth Company | false |